Although causal relationships between the KP and diseases are uncertain, modulation of the KP by enzyme inhibitors or KP metabolites has been proposed for the prevention and treatment of a range of both benign and malignant diseases, such as neurological, psychiatric, metabolic, and intestinal diseases [2,3,12]. The gene discussed is NPPA; the disease is intestinal disorder.